Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
ConditionRectal Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorMayo Clinic
About this trial
This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.
Eligibility criteria
Qualifiers
Adult patients 18 to 99 years of age
Patients with proven rectal cancer clinically referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis (for evaluation of liver and peritoneal disease)
Endoscopic or imaging report that tumor is 2 cm or larger
Patients who are able and willing to sign the informed consent
Disqualifiers
Minors less than 18 years old
Patient unable to provide written informed consent
Pregnancy
Estimated Glomerular Filtration Rate (eGFR) ≤ 60
Trial design
Treatments tested in this trial
- PCD-CT
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov